Medicine and Dentistry
Neoplasm
100%
Nivolumab
66%
Glioblastoma
66%
Bevacizumab
66%
Arm
35%
T Cell Activation
33%
Autologous Tumor Cell
33%
Personalized Medicine
33%
Adjuvant
33%
Metastatic Melanoma
33%
Tumor Infiltrating Lymphocyte
29%
Immunotherapy
17%
T Cell
16%
T-Cell Response
13%
Immune Response
13%
Biopsy
10%
Clinical Trial
8%
Immunoglobulin G4
7%
Brain Tumor
7%
Surgery
7%
Immune Checkpoint Inhibitor
6%
Interim Analysis
6%
Liposome
6%
Adverse Event
6%
Next Generation Sequencing
6%
Cancer Vaccine
6%
Synthetic Peptide
6%
Cytotoxic T-Cell
6%
Immunology and Microbiology
Vaccine Efficacy
80%
Neoantigen
76%
Nivolumab
66%
T Cell
55%
Immunotherapy
41%
Tumor-Associated Macrophage
33%
Bevacizumab
33%
Adjuvant
33%
Tumor Cell
33%
Arm
20%
Immune Response
17%
T-Helper Cell
14%
Cytotoxic T-Cell
13%
Artificial Intelligence
13%
Immunogenicity
9%
Cancer Cell
9%
Peptide Vaccine
9%
CD4
8%
CD39 Antigen
5%
Keyphrases
Surgical Arm
9%
Artificial Intelligence Platform
8%
Competitive Manufacturing
8%
Baseline Biopsy
8%
Interim Analysis
8%
AI Platform
8%
Interim Data
8%
Objective Tumor Response
8%
Vaccine Peptide
6%
Cancer Heterogeneity
6%
Immune Checkpoint Inhibitor Resistance
6%
Neurosurgical Resection
5%
Tumor Clearance
5%
CD39
5%
Dismal Prognosis
5%
IgG4-positive
5%
